DKA has been observed in T2D patients taking Glucagon-Like Peptide 1 Receptor (GLP-1) agonists and Dipeptidyl peptidase-4 (DPP-4) inhibitors9,10. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.